Research programme: rheumatoid arthritis therapy - Sanofi
Alternative Names: RB-2002; RB-2003Latest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Class
- Mechanism of Action Macrophage inhibitors; Nitric oxide synthase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 May 2006 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 30 Mar 2004 SangStat's operations have been absorbed into Genzyme Corporation's Cambridge site
- 14 Nov 2003 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)